Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
The Dermatology Nurses’ Association hosts its 43rd yearly meeting in Orlando, FL, March 5–8, 2025, offering in-person educational and networking opportunities to promote patient care excellence.
The Dermatology Nurses’ Association hosts its 43rd yearly meeting in Orlando, FL, March 5–8, 2025, offering in-person educational and networking opportunities to promote patient care excellence.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.